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Despite dramatic improvements in the primary success rate 
of coronary balloon angioplasty (1), the long-term efficacy of 
the procedure has not increased since its inception in 1977 
(2,3). This paradox has been due to an unabated 30% to 40% 
incidence rate of re stenosis that has persisted despite multi-
ple attempted pharmacologic (4) and mechanical interven-
tions (5,6). 
The problem of coronary restenosis. The pathogenesis of 
the restenotic response to mechanical injury is incompletely 
understood (7); clearly it is multifactorial and includes 
growth factor stimulation of smooth muscle proliferation 
(8-10), elastic recoil (ll) and organization of thrombus 
adherent at the site of arterial injury (12). Our understanding 
of the problem has been limited by the lack of an animal 
model that adequately mimics the pathologic response of the 
diseased human artery to balloon trauma. The rabbit iliac 
and rat carotid artery models, for example, have suggested 
benefit from at least nine pharmacologic interventions, none 
of which inhibited restenosis in later human testing (albeit 
often at a lower drug dosage) (13). The use of other models, 
such as the nonhuman primate, has also been limited by high 
purchase and maintenance costs and by difficulties in han-
dling of the animals. 
Our understanding of restenosis has been further ham-
pered by inadequate methods for measuring its prevalence in 
humans. The previous reference standard, percent diameter 
stenosis determined by contrast angiography, is now recog-
nized to be a poor one, in large part because measurement of 
the adjacent "normal" artery is required; this reference 
segment is seldom normal, but instead, is usually diseased 
(14). Similarly, measurement of absolute minimal lumen 
dimension by quantitative angiography is limited because 
multiple views are required to adequately define eccentric 
stenoses and the highly irregular lumen borders produced by 
balloon angioplasty (15,16). Consistent with this limitation is 
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the observation that postangioplasty dimensions as mea-
sured by intravascular ultrasound, a technique still in in-
fancy itself, are consistently 15% to 30% smaller than lumen 
diameters measured by quantitative contrast angiography 
(17). 
The present studies. Two reports in this issue of the 
Journal add to our understanding of the problem. Schwartz 
and colleagues (18), using the depth of arterial wall penetra-
tion by the wires of tantalum stents introduced and overex-
panded by a balloon angioplasty catheter, describe a propor-
tional response between the degree of arterial injury and the 
severity of neointimal thickening in a porcine coronary 
model. This important observation extends the work of 
Steele (19) and Wilentz (20) and their coworkers, who 
described a proportional response between the degree of 
injury and early platelet deposition in other models. If 
validated, this concept might greatly increase the sensitivity 
for detecting potentially useful interventions by allowing 
correction of the severity of neointimal thickening for the 
variable degree of arterial injury. However, it is not clear if 
this model usefully mirrors the human response (in fact the 
response may be so exuberant that it is insensitive to 
potentially useful interventions). Further, although more late 
thickening was seen with greater damage, this finding does 
not give the interventional cardiologist any indication of how 
much damage to inflict, as some balloon stretch is required 
to achieve an initial dimensional gain. Finally, one must not 
conclude from this study that the stent itself causes prolific 
restenosis, as in this study the stent was intentionally very 
much oversized (stent/artery ratio 1.3 to 2) compared with 
the stent/artery ratio of 1 to 1.1 that is currently being 
evaluated in clinical trials. 
The clinical correlate of the proportional response of 
Schwartz et al. (18) is described, also in this issue of the 
Journal, by Beatt and colleagues (21). They used computer-
assisted quantitative coronary angiography to assess 490 
lesions from 424 patients obtained 94 ± 43 days after 
coronary angioplasty. Re stenosis, defined as a decrease in 
minimal lumen dimension from the postprocedure result by 
~o. 72 mm, was found to be significantly correlated with both 
larger improvement at the time of dilation and with a larger 
absolute dimension after angioplasty. They conclude that 
increased mechanical stretch leads to more lumen renarrow-
ing. Also, and very important, they conclude that a distinc-
tion should be made between clinical restenosis (as mea-
sured by the ~50% stenosis definition) and the restenosis 
process (as measured by dimensional change after angio-
plasty). However, the clinician is again not provided with 
enough information to judge the angiographic result he or 
she should strive for, as the clinical result in relation to 
postangioplasty dimension is not given. Hence, the appro-
priate balance between sufficient trauma to produce an 
adequate platform to minimize the clinical effect of the 
anticipated myointimal regrowth and limited trauma so as 
not to trigger an exuberant response cannot be judged. 
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Optimal model for human restenosis. While one can spec-
ulate that the ideal model should have pathologic features 
similar to those of humans before and after arterial injury, 
and should perhaps also respond similarly to dietary manip-
ulation, it remains unclear whether these factors are prereq-
uisite. Most important, the optimal model for restenosis 
should accurately predict the impact of pharmacologic and 
mechanical interventions in humans. If an intervention is 
beneficial in the model then benefit should be clearly demon-
strable in human studies and, conversely, its negative pre-
dictive value should also be high. Unfortunately, no inter-
vention shown to be effective in an animal model has 
reproducibly been shown to have even a small benefit in 
humans. Although this is likely to be due primarily to the 
shortcomings of the animal models, it may also be a function 
of inadequacies of trial design and inappropriate use or 
incomplete assessment of the end points used in many 
clinical trials (see later). 
Optimal definition ofrestenosis. As noted previously (22), 
the incidence and clinical implications of the restenosis 
process vary considerably according to the criteria used to 
define this entity. In the study of Beatt et al. (21), the 
definition of a ~50% diameter stenosis at follow-up angiog-
raphy identified a different group of patients from the group 
with restenosis defined by a change in minimal lumen 
diameter ~0.72 mm. Both definitions have important limita-
tions. The rationale for the former criterion is that a measure 
of stenosis severity should reflect coronary flow reserve and 
thus be functionally and physiologically relevant (23). How-
ever, the definition assumes that the proximal or distal 
reference segment is not diseased and that no change has 
occurred in its caliber, assumptions that have been clearly 
shown to be invalid (14,22). Moreover, this definition may 
exclude patients with a considerable degree of neointimal 
thickening after an optimal angioplasty result but include 
patients with only a mild degree of neointimal thickening 
after a suboptimal angioplasty result. Finally, the arbitrary 
definition of ~50% diameter stenosis does not take into 
consideration the effects on coronary flow of stenosis length 
or angulation, dynamic changes in vessel caliber due to 
compensatory dilation, or the inaccuracies in measuring 
diameter stenosis in patients with diffuse coronary disease. 
Although some of these difficulties are addressed using 
the change in minimal lumen diameter definition, this too has 
limitations. First, 0.72 mm is twice the standard deviation for 
repeated measures of nondilated coronary artery stenoses. 
This measurement has not been validated for angiography 
performed after coronary balloon dilation, a procedure that 
frequently causes lumen irregularities and haziness at the 
site of dilation. Second, a change of 0.72 mm has no 
physiologic meaning unless it is corrected for the caliber of 
the reference segment; it is thus also limited by the changes 
in caliber that may occur at this site. Third, the numeric 
change in minimal lumen diameter does not identify the 
nature of the "restenosis process" in any given individual. 
In the absence of ancillary investigations such as intracoro-
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nary ultrasound or local biopsy, however, it is unlikely that 
any angiographic measurement will distinguish between in-
timal proliferation, organized mural thrombus and elastic 
recoil. Finally, although measured as a continuous variable, 
the use of the binary outcome ~0. 72 mm change in minimal 
lumen diameter, like the use of ~50% diameter stenosis, 
limits the statistical power of the observation. This has 
important implications for clinical trial design. If a binary 
definition is used, 696 patients must be enrolled with com-
plete angiographic follow-up to have an 80% certainty of 
detecting a reduction in the incidence of restenosis in a given 
population from 35% to 25% with 2p = 0.05. If, on the other 
hand, a continuous variable is used, only about 100 patients 
would be required to demonstrate the same difference with 
the same statistical certainty. Using this approach a small 
difference in minimal lumen dimension might be statistically 
significant but its clinical relevance would have to be tested. 
With these limitations in mind, we would recommend that 
the primary end point for angiographic trials assessing phar-
macologic interventions should be absolute dimensional 
change, rather than "percent diameter stenosis." For me-
chanical interventions, that may intentionally trade off some 
lumen regrowth for a larger postprocedure platform, an end 
point of follow-up minimal lumen dimension would be more 
appropriate. Normalization for the diameter of the adjacent 
vessel at the time of the initial intervention should also be 
performed for interventions that are used in arteries of 
widely varying caliber. 
Strategy for testing interventions. A number of large 
clinical trials have already been performed on the basis of 
little solid pretrial evidence that the intervention might 
actually work. The cost of this practice to the pharmaceuti-
cal industry, and eventually to society, is immense. Con-
versely, if a given intervention can be shown to have even a 
small impact on the incidence of restenosis, the potential 
savings in health care costs would be considerable. A 
three-stage testing scheme could be advanced as a rational, 
and probably most cost-effective, approach. First, any inter-
vention considered to be effective on the basis of cell culture 
testing, or response in related disease processes, should be 
tested in at least two animal models. Second, if shown 
effective in animal models, the intervention should then be 
tested in a relatively small scale angiographic trial (for 
example, lOO patients restudied at 6 months) with minimal 
lumen dimension, measured as a continuous variable, as the 
primary end point. Only then is a full scale clinical trial in 
order. This would likely require 600 to 1,000 patients. 
Contrast angiography cannot adequately serve as the sole 
end point for such a trial because other clinically meaningful 
events, such as myocardial infarction and stroke, might also 
be influenced by individual pharmacologic interventions. 
Response to formal exercise testing has also been advocated 
as an end point for such a study because of the imperfect 
relation between stenosis dimensions and physiologic varia-
bles (22). Such testing may be invalid, however, because of 
progression of other nondilated stenoses, or unreliable be-
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cause of other exercise limiting variables (for example, 
chronic pulmonary diseases). Perhaps more appropriate 
would be a composite clinical end point, similar to that 
advocated by Califf et al. (24) as an end point for throm-
bolytic trials. One could envision the following hierarchy of 
clinical outcomes: death, nonfatal myocardial infarction or 
stroke, repeat intervention (angioplasty or bypass surgery 
for documented recurrent stenosis at the dilated site), an 
abnormal stress test result without angiography, loss of 
patient to follow-up, negative functional test with suboptimal 
provocation and, finally, negative functional test with an 
adequate work load. 
Thus, although the ultimate answer or solution to the 
restenosis problem will almost undoubtedly be found in the 
future using the tools of molecular biology or possibly gene 
therapy, rational testing for benefit can probably be im-
proved on by using fundamental knowledge available today. 
References 
I. Detre KM, Holubkov R, Kelsey SF, et al. Percutaneous transluminal 
coronary angioplasty in 1985-86 and 1977-81. N Engl J Med 1988;318: 
265-70. 
2. Gruentzig AR, King SB, Schlumpf M, Siegenthaler W. Long-term 
follow-up after percutaneous transluminal angioplasty: the early Zurich 
experience. N Engl J Med 1987;316: 1127-32. 
3. Detre D, Holubkov R, Kelsey S, et al. One-year follow-up results of the 
1985-86 National Heart, Lung, and Blood Institute's Percutaneous Trans-
luminal Coronary Angioplasty Registry. Circulation 1989;80:421-8. 
4. CaliffRM, Ohman EM, Frid DJ, et al. Restenosis: the clinical issues. In: 
Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia: WB 
Saunders, 1991:363-94. 
5. Roubin GS, Douglas JS, King SB, et al. InHuence of balloon size on initial 
success, acute complications, and restenosis after percutaneous translum-
inal coronary angioplasty. Circulation 1988;78:557-65. 
6. Lancelin B, Chevalier B, Guyton P, Aziza JP. Failure of prolonged 
balloon inHation during coronary angioplasty to prevent restenosis 
(abstr). Circulation 1989;80(Suppl 11):11-260. 
7. Liu MW, Roubin GS, King SB. Restenosis after coronary angioplasty: 
potential biologic determinants and role of intimal hyperplasia. Circula-
tion 1989;79:1374-87. 
8. Stiles CD, Pledger WJ, Tucker RW, Martin RG, Scher CD. Regulation of 
the Balb/C-T3T3 cell cycle effects of growth factors. J Supramol Struct 
1980;13:489-99. 
ELLIS AND MULLER 
EDITORIAL COMMENT 
277 
9. Assoian RK, Grotendorst GR, Miller DM, Spom MG. Cellular transfor-
mation by coordinate action of three peptide growth factors from human 
platelets. Nature 1984;309:804-6. 
10. Reidy MA, Walker LN. Endothelial-smooth muscle cell interaction in 
vivo. In: Strandness D, Didisheim P, Clowes A, Watson J, eds. Vascular 
Disease. Orlando, FL: Grune & Stratton, 1987:185-95. 
11. Wailer BF, Pinkerton CA. "Cutters, scoopers, shavers and scrapers": 
the importance of atherectomy devices and clinical relevance of tissue 
removed. J Am Coli Cardiol 1990;15:426-8. 
12. Dick RJ, Haudenschild C, Popma JJ, Yakubov S, Topol EJ. lnsights from 
quantitative histologic analysis of excisional atherectomy specimens 
(abstr). Circulation 1990;82(suppl III):III-311. 
13. Muller DWM, Ellis SG, Topol EJ . Experimental models of coronary 
artery restenosis. JAm Coli Cardiol 1991 ;19:418-32. 
14. Arnett EN, Isner JM, Redwood OR, et al. Coronary artery narrowing in 
coronary heart disease: comparison of cineangiographic and necropsy 
findings. Ann Intern Med 1979;91:350-6. 
15. Spears JR, Sandor T, Bairn OS, Paulin S. The minimum error in 
estimating coronary luminal cross-sectional area from cineangiographic 
diameter measurements. Cathet Cardiovasc Diagn 1983;9:119-28. 
16. Isner JM, Rosenfield K, Losordo DW, et al. Combination balloon-
ultrasound imaging from percutaneous transluminal angioplasty: valida-
tion of imaging, analysis of recoil, and identification of plaque fracture . 
Circulation 1991 ;84:739-54. 
17. Gurley JC, Nissen SE, Grines CL, Booth DC, Fischer C, DeMaria A. 
Comparison of intravascular ultrasound and angiography following per-
cutaneous transluminal coronary angioplasty (abstr). Circulation 1990; 
82(suppl III):III-72. 
18. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the propor-
tional neointimal response to coronary artery injury: results in a porcine 
model. J Am Coli Cardiol 1992;19:267-74. 
19. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty: natural 
history of the pathophysiologic response to injury in a pig model. Circ Res 
1985;57:105-12. 
20. Wilentz JR, Sanbom TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon 
DP. Platelet accumulation in experimental angioplasty: time course and 
relation to vascular injury. Circulation 1987;75:636-42. 
21. Beatt KJ , Serruys PW, Luijten HE, et al. Restenosis after coronary 
angioplasty: the paradox of increased lumen diameter and restenosis. 
JAm Coli Cardioll991 ;19:258-66. 
22. Serruys PW, Luijten HE, Beatt KJ , et al. Incidence of restenosis after 
successful coronary angioplasty: a time-related phenomenon. Circulation 
1988;77:361-71. 
23. Harrison DG, White CW, Hiratzka LF, et al. Can the significance of a 
coronary stenosis be predicted by quantitative coronary angiography? 
Circulation 1981 ;64: 160-8. 
24. Califf RM, Fortin DF, Frid DJ, et al. Restenosis after coronary angio-
plasty: an overview. JAm Coli Cardioii991 ;17:2B-13B. 
